BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The Closing Print//Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The Closing Print
BEGIN:VEVENT
SUMMARY:TCP: ImmunityBio (IBRX) Q3 2026 earnings (estimated)
DTSTART;VALUE=DATE:20261104
DTEND;VALUE=DATE:20261105
DTSTAMP:20261104T130004Z
UID:2026-11-04-ibrx-q3-earnings@theclosingprint.net
DESCRIPTION:ImmunityBio Q3 2026 results\; date not yet announced (company 
 reported Nov 4 last year).\nSource: https://ir.immunitybio.com/\nDate/time
  is an estimate and may change.\nCoverage: https://www.theclosingprint.net
 /2026/11/immunitybio-ibrx-q3-2026-earnings-preview/\n\nMore analysis at Th
 e Closing Print: https://www.theclosingprint.net
TRANSP:TRANSPARENT
URL:https://www.theclosingprint.net/2026/11/immunitybio-ibrx-q3-2026-earni
 ngs-preview/
X-ALT-DESC;FMTTYPE=text/html:<html><body>ImmunityBio Q3 2026 results; date
  not yet announced (company reported Nov 4 last year).<br>Source: https://
 ir.immunitybio.com/<br>Date/time is an estimate and may change.<br>Coverag
 e: https://www.theclosingprint.net/2026/11/immunitybio-ibrx-q3-2026-earnin
 gs-preview/<br><br>More analysis at The Closing Print: <a href="https://ww
 w.theclosingprint.net">https://www.theclosingprint.net</a></body></html>
BEGIN:VALARM
ACTION:DISPLAY
DESCRIPTION:ImmunityBio (IBRX) Q3 2026 earnings (estimated)
TRIGGER:-P1D
END:VALARM
END:VEVENT
BEGIN:VEVENT
SUMMARY:TCP: SITC 2026 annual meeting (Phoenix)\, Nov 4-8
DTSTART;VALUE=DATE:20261104
DTEND;VALUE=DATE:20261105
DTSTAMP:20261104T130004Z
UID:sitc-2026@theclosingprint.net
DESCRIPTION:Society for Immunotherapy of Cancer annual meeting\, Phoenix\,
  Nov 4-8\, 2026. ImmunityBio lists it among upcoming events.\nSource: http
 s://ir.immunitybio.com/company/events-and-presentations\nCoverage: https:/
 /www.theclosingprint.net/2026/11/immunitybio-ibrx-q3-2026-earnings-preview
 /\n\nMore analysis at The Closing Print: https://www.theclosingprint.net
TRANSP:TRANSPARENT
URL:https://www.theclosingprint.net/2026/11/immunitybio-ibrx-q3-2026-earni
 ngs-preview/
X-ALT-DESC;FMTTYPE=text/html:<html><body>Society for Immunotherapy of Canc
 er annual meeting, Phoenix, Nov 4-8, 2026. ImmunityBio lists it among upco
 ming events.<br>Source: https://ir.immunitybio.com/company/events-and-pres
 entations<br>Coverage: https://www.theclosingprint.net/2026/11/immunitybio
 -ibrx-q3-2026-earnings-preview/<br><br>More analysis at The Closing Print:
  <a href="https://www.theclosingprint.net">https://www.theclosingprint.net
 </a></body></html>
BEGIN:VALARM
ACTION:DISPLAY
DESCRIPTION:SITC 2026 annual meeting (Phoenix)\, Nov 4-8
TRIGGER:-P1D
END:VALARM
END:VEVENT
BEGIN:VEVENT
SUMMARY:TCP: ImmunityBio QUILT-2.005 topline results (expected in November
 \, estimated)
DTSTART;VALUE=DATE:20261105
DTEND;VALUE=DATE:20261201
DTSTAMP:20261104T130004Z
UID:ibrx-quilt-2005-topline-nov@theclosingprint.net
DESCRIPTION:ImmunityBio expects topline results from the randomized QUILT-
 2.005 trial of ANKTIVA plus BCG vs BCG alone in BCG-naive NMIBC in Novembe
 r 2026\; exact date not announced.\nDate/time is an estimate and may chang
 e.\nCoverage: https://www.theclosingprint.net/2026/11/immunitybio-ibrx-q3-
 2026-earnings-preview/\n\nMore analysis at The Closing Print: https://www.
 theclosingprint.net
TRANSP:TRANSPARENT
URL:https://www.theclosingprint.net/2026/11/immunitybio-ibrx-q3-2026-earni
 ngs-preview/
X-ALT-DESC;FMTTYPE=text/html:<html><body>ImmunityBio expects topline resul
 ts from the randomized QUILT-2.005 trial of ANKTIVA plus BCG vs BCG alone 
 in BCG-naive NMIBC in November 2026; exact date not announced.<br>Date/tim
 e is an estimate and may change.<br>Coverage: https://www.theclosingprint.
 net/2026/11/immunitybio-ibrx-q3-2026-earnings-preview/<br><br>More analysi
 s at The Closing Print: <a href="https://www.theclosingprint.net">https://
 www.theclosingprint.net</a></body></html>
BEGIN:VALARM
ACTION:DISPLAY
DESCRIPTION:ImmunityBio QUILT-2.005 topline results (expected in November
 \, estimated)
TRIGGER:-P1D
END:VALARM
END:VEVENT
BEGIN:VEVENT
SUMMARY:ImmunityBio Q3 2026 conference call (estimated)\, tracked by TCP
DTSTART:20261113T143000Z
DTEND:20261113T153000Z
DTSTAMP:20261104T130004Z
UID:ibrx-q3-2026-call@theclosingprint.net
DESCRIPTION:ImmunityBio third-quarter 2026 conference call\, 9:30 AM ET. D
 ate and time not yet confirmed by the company.\nDate/time is an estimate a
 nd may change.\nCoverage: https://www.theclosingprint.net/2026/11/immunity
 bio-ibrx-q3-2026-earnings-preview/\n\nMore analysis at The Closing Print: 
 https://www.theclosingprint.net
URL:https://www.theclosingprint.net/2026/11/immunitybio-ibrx-q3-2026-earni
 ngs-preview/
X-ALT-DESC;FMTTYPE=text/html:<html><body>ImmunityBio third-quarter 2026 co
 nference call, 9:30 AM ET. Date and time not yet confirmed by the company.
 <br>Date/time is an estimate and may change.<br>Coverage: https://www.thec
 losingprint.net/2026/11/immunitybio-ibrx-q3-2026-earnings-preview/<br><br>
 More analysis at The Closing Print: <a href="https://www.theclosingprint.n
 et">https://www.theclosingprint.net</a></body></html>
BEGIN:VALARM
ACTION:DISPLAY
DESCRIPTION:ImmunityBio Q3 2026 conference call (estimated)
TRIGGER:-P1D
END:VALARM
END:VEVENT
BEGIN:VEVENT
SUMMARY:ImmunityBio BCG-naive sBLA submission target (Q4 2026) (estimated)
 \, tracked by TCP
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
DTSTAMP:20261104T130004Z
UID:2026-12-31-ibrx-bcg-naive-sbla@theclosingprint.net
DESCRIPTION:ImmunityBio targets submitting a supplemental BLA for ANKTIVA 
 plus BCG in BCG-naive NMIBC by the end of Q4 2026.\nDate/time is an estima
 te and may change.\nCoverage: https://www.theclosingprint.net/2026/11/immu
 nitybio-ibrx-q3-2026-earnings-preview/\n\nMore analysis at The Closing Pri
 nt: https://www.theclosingprint.net
TRANSP:TRANSPARENT
URL:https://www.theclosingprint.net/2026/11/immunitybio-ibrx-q3-2026-earni
 ngs-preview/
X-ALT-DESC;FMTTYPE=text/html:<html><body>ImmunityBio targets submitting a 
 supplemental BLA for ANKTIVA plus BCG in BCG-naive NMIBC by the end of Q4 
 2026.<br>Date/time is an estimate and may change.<br>Coverage: https://www
 .theclosingprint.net/2026/11/immunitybio-ibrx-q3-2026-earnings-preview/<br
 ><br>More analysis at The Closing Print: <a href="https://www.theclosingpr
 int.net">https://www.theclosingprint.net</a></body></html>
BEGIN:VALARM
ACTION:DISPLAY
DESCRIPTION:ImmunityBio BCG-naive sBLA submission target (Q4 2026) (estima
 ted)
TRIGGER:-P1D
END:VALARM
END:VEVENT
END:VCALENDAR